UA new study by French researchers, released this Monday, demonstrates that the vaccine produced a robust immune response against the Delta variant in adults aged 50 to 72 years, decreasing hospitalizations and deaths from Covid-19.
The Epi-Phare study focused on analyzing data collected between December 2020 and July 2021, referring to French citizens over 50 and vaccinated with Pfizer/BioNtech, Moderna or AstraZeneca. However, researchers recall that the Delta variant only became dominant in the country in July of this year.
As the study explains, participants aged 50 to 75 with full vaccination developed 92% more effective antibodies against the Delta variant, first detected in India.
Vaccination was also effective in 84% of people over 75, after a period of about 14 days after the last or only vaccination course.
Also Read: Covid-19: Third-Dose Vaccination of Older Persons Starts This Week
Always be the first to know.
Fifth consecutive year Consumer Choice for Online Press.
Download our free App.